$NOVT

Glastra Matthijs sold $238K of NOVT

Glastra Matthijs (Chief Executive Officer) sold 1,420 shares of NOVANTA INC (NOVT) at $167.68 ($0.24M total) on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Glastra Matthijs
Published Jun 4, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NOVT
Neutral
medium confidence
Mentioned
$NOVT
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NOVTNeutralLow
01

Why it matters

The disclosure updates insider ownership records but does not, by itself, change the company’s fundamentals or guidance.

02

Market read

Traders may monitor insider activity as a sentiment input, but this specific filing is unlikely to drive a major repricing absent additional catalysts.

03

What to watch

10b5-1 plans can be scheduled regardless of near-term news; the sale size/value ($238k) may be too small to materially change investor expectations.

Relevance 6/10Novelty 3/10Timing: Filed after-hours on 2026-06-04; transaction executed 2026-06-02.

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by the CEO under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$NOVTNeutralMedium confidence
Context

Novanta CEO Glastra Matthijs filed an open-market sale of 1,420 shares at $167.68 under a 10b5-1 plan.

Expected impact

Near-term impact likely modest; any reaction may fade unless accompanied by other negative disclosures.

Evidence & confidence

The filing is a routine 10b5-1 sale by an officer, not a surprise change in business outlook or capital allocation.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide trigger.

None indicated.

None indicated.

Counterpoint

If the market interprets officer selling as a stronger-than-expected confidence signal, short-term downside pressure could occur despite 10b5-1 labeling.

Key entities

  • Novanta Inc

    Subject of the Form 4 insider transaction disclosure.

  • Glastra Matthijs

    Novanta CEO and reporting person who sold shares.

Related articles

$NOVTHighAI 9/10

Novanta Announces Financial Results for the Second Quarter 2026

Novanta Inc. (Nasdaq: NOVT) reported Q2 2026 GAAP revenue of $265.8 million, up 10.3% year over year, and GAAP net income of $12.5 million. Adjusted EBITDA rose 16.4% to $60.7 million and adjusted diluted EPS increased 17.1% to $0.89. The company also closed the Riverpoint Medical acquisition and raised Q3 and FY 2026 guidance.

$NOVTHigh

NOVANTA INC (NOVT): Results of Operations and Financial Condition

NOVANTA INC (NOVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 novt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE August 5, 2026 Novanta Announces Financial Results for the Second Quarter 2026 • Second Quarter 2026 GAAP Revenue increased 10% to $266 million • Second Quarter 2026 GAAP Net Income was $13 million, and

$NOVTMedAI 8/10

Novanta Completes Acquisition of Riverpoint Medical

Novanta Inc. (Nasdaq: NOVT) said it has completed its acquisition of Riverpoint Medical from Arlington Capital Partners. Novanta expects the deal to double recurring medical consumables revenue to about $300 million, raise medical end-market exposure to 60%, deliver high single-digit ROIC by year three, and add $0.18 to $0.25 of adjusted EPS in 2027.

$MRVLMed

Stocks Erase Early Gains as Chipmakers Turn Lower

US stocks pared early gains as chipmakers and software firms fell. Marvell, Qualcomm, ARM and others dropped, while ServiceNow and Salesforce also declined. Treasury yields were pressured by a $58B 3-year auction and stronger May existing home sales. In Europe, Bund and gilt yields fell; swaps price a 100% chance of a 25 bp ECB hike. UNFI slid after Q3 sales missed; Nuvalent surged on a $10.6B GSK buyout.